Table 4.

Multivariate analysis for aGVHD, cGVHD, TRM, relapse, treatment failure, and overall survival

Outcome
RR (95% CI)
P
aGVHD   
    Mismatch related vs HLA-identical sibling   1.57 (1.06-2.33)   .024  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   1.68 (1.09-2.60)   .020  
            ABO blood group    
                Matched   1.00   .033† 
                Minor mismatched   0.42 (0.22-0.81)   .009  
                Major mismatched   0.93 (0.61-1.42)   .733  
cGVHD   
    Mismatch related vs HLA-identical sibling   0.99 (0.72-1.38)   .969  
TRM*   
    Mismatch related vs HLA-identical sibling   1.75 (0.99-3.09)   .054  
Relapse   
    Mismatch related vs HLA-identical sibling   0.86 (0.45-1.65)   .653  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   5.69 (2.92-11.09)   < .001  
            Disease type    
                ALL   1.00   .002† 
                AML   0.75 (0.36-1.56)   .436  
                CML   0.24 (0.09-0.59)   .002  
                MDS   0.12 (0.03-0.53)   .005  
Treatment failure   
    Mismatch related vs HLA-identical sibling   1.23 (0.80-1.89)   .351  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   3.23 (1.99-5.24)   < .001  
            Disease type    
                ALL   1.00   .015† 
                AML   0.92 (0.55-1.57)   .771  
                CML   0.55 (0.33-0.94)   .027  
                MDS   0.29 (0.12-0.74)   .010  
Overall survival   
    Mismatch related vs HLA-identical sibling   1.12 (0.71-1.76)   .620  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   3.30 (2.00-5.45)   < .001  
            Disease type    
                ALL   1.00   .028† 
                AML   0.85 (0.49-1.50)   .584  
                CML   0.57 (0.33-0.98)   .043  
                MDS
 		 0.27 (0.10-0.74)
 		 .011
 
Outcome
RR (95% CI)
P
aGVHD   
    Mismatch related vs HLA-identical sibling   1.57 (1.06-2.33)   .024  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   1.68 (1.09-2.60)   .020  
            ABO blood group    
                Matched   1.00   .033† 
                Minor mismatched   0.42 (0.22-0.81)   .009  
                Major mismatched   0.93 (0.61-1.42)   .733  
cGVHD   
    Mismatch related vs HLA-identical sibling   0.99 (0.72-1.38)   .969  
TRM*   
    Mismatch related vs HLA-identical sibling   1.75 (0.99-3.09)   .054  
Relapse   
    Mismatch related vs HLA-identical sibling   0.86 (0.45-1.65)   .653  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   5.69 (2.92-11.09)   < .001  
            Disease type    
                ALL   1.00   .002† 
                AML   0.75 (0.36-1.56)   .436  
                CML   0.24 (0.09-0.59)   .002  
                MDS   0.12 (0.03-0.53)   .005  
Treatment failure   
    Mismatch related vs HLA-identical sibling   1.23 (0.80-1.89)   .351  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   3.23 (1.99-5.24)   < .001  
            Disease type    
                ALL   1.00   .015† 
                AML   0.92 (0.55-1.57)   .771  
                CML   0.55 (0.33-0.94)   .027  
                MDS   0.29 (0.12-0.74)   .010  
Overall survival   
    Mismatch related vs HLA-identical sibling   1.12 (0.71-1.76)   .620  
        Other significant risk factors    
            Disease stage before transplantation    
                Advanced vs early/intermediate   3.30 (2.00-5.45)   < .001  
            Disease type    
                ALL   1.00   .028† 
                AML   0.85 (0.49-1.50)   .584  
                CML   0.57 (0.33-0.98)   .043  
                MDS
 		 0.27 (0.10-0.74)
 		 .011
 
*

Based on final model, a GVHD and cGVHD had significant effect on TRM: RR (95% CI) for aGVHD of grades II to IV versus 0 to I = 1.90 (1.08-3.34; P = .026), for cGVHD of yes versus no = 2.77 (1.26-6.07; P = .011).

†

Three degrees of freedom test.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal